VRC-HIVMAB0121-00-AB (CAP256J3LS)

· National Institute of Allergy and Infectious Diseases (NIAID)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for VRC-HIVMAB0121-00-AB (CAP256J3LS), covering 2026-03-23 to 2026-03-23. Get the full timeline:

Most recent: Clinical Trial Update: Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults [Phase 1]

See pricing